OPTIMASH® AD-300 – the sole protease-only enzyme on the market – offers biogas plant operators around the world an enzyme solution for increased yields and efficiency

AMSTERDAM, Oct. 30, 2017 – DuPont Industrial Biosciences announced today a new enzyme product designed to improve biogas production during anaerobic digestion in the waste water industry: DuPont™ OPTIMASH® AD-300. The announcement comes at the Aquatech Amsterdam conference, where DuPont will be launching the enzyme offering to the industry. The enzyme is immediately available to producers in markets around the world.

Optimash® AD-300, a protease-only product, is effective at breaking down organic materials that contain protein, such as wastewater sludge, food waste, animal and farm wastes. It functions by breaking down the protein polymers, resulting in soluble amino acids that are more suitable for biogas-producing organisms.

By incorporating the protease into their digester, biogas plant operators can expect numerous benefits, including: more efficient use of proteinaceous materials; increased biogas production; increased fermentation rate and shorter residence time; greater feedstock flexibility; increased process robustness and further reduction of volatile solids.

“From conception through development, we have prioritized our customers’ desire for increased production and efficiency, and as the sole protease-only product on the market, we are able to deliver,” said Sandra Hinz, Ph.D., senior scientist at DuPont Industrial Biosciences. “Our approach with this enzyme is to offer a specific and targeted product that biogas producers can dial in based on their needs, instead of buying a costly packaged enzyme solution.”

The enzyme can be introduced into any biogas process, including in a pretreatment, separate hydrolysis step, as well as directly into a primary fermenter. DuPont’s technical sales professionals are committed to working with biogas producers to determine specific process recommendations based on feedstock material, objectives and plant characteristics. Also, identifying the addition point that maximizes enzyme access to the feedstock is vital to fully exploiting the benefits of enzymes.

In recent years, DuPont Industrial Biosciences has focused its biotechnology expertise and robust enzyme portfolio on the realm of biogas. In August, the company received a grant from the European Commission to demonstrate high-efficiency enzyme production to increase biogas yields as part of the DEMETER project. Funded from the Bio Based Industries Joint Undertaking under the European Union’s Horizon 2020 Research and Innovation program, DEMETER aims to demonstrate the enzyme technology’s ability to improve biogas yields and process robustness, ultimately increasing customers’ revenue and profitability, while increasing offerings in renewable energy.

About Industrial Biosciences

DuPont Industrial Biosciences works with customers across a wide range of industries to make products and industrial processes more efficient and sustainable. Through a unique combination of agriculture, biotechnology, chemistry and material science capabilities, we advance market-driven, bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. For updates about how DuPont Industrial Biosciences is helping customers deliver cost-effective products with superior performance and sustainability, follow @DuPontBiobased on Twitter or visit our website at http://biosciences.dupont.com.

About DowDuPont Specialty Products Division

DowDuPont Specialty Products, a division of DowDuPont (NYSE: DWDP), is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, building and construction, health and wellness, food and worker safety. DowDuPont intends to separate the Specialty Products division into an independent, publicly traded company. More information can be found www.dow-dupont.com.

Cautionary Statement About Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words.

On December 11, 2015, The Dow Chemical Company (“Dow”) and E. I. du Pont de Nemours and Company (“DuPont”) announced entry into an Agreement and Plan of Merger, as amended on March 31, 2017, (the “Merger Agreement”) under which the companies would combine in an all-stock merger of equals transaction (the “Merger Transaction”). Effective August 31, 2017, the Merger Transaction was completed and each of Dow and DuPont became subsidiaries of DowDuPont Inc. (“DowDuPont”). For more information, please see each of DowDuPont’s, Dow’s and DuPont’s latest annual, quarterly and current reports on Forms 10-K, 10-Q and 8-K, as the case may be, and the joint proxy statement/prospectus included in the registration statement on Form S-4 filed by DowDuPont with the SEC on March 1, 2016 (File No. 333-209869), as last amended on June 7, 2016, and declared effective by the SEC on June 9, 2016 (the “Registration Statement”) in connection with the Merger Transaction.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, including the intended separation of DowDuPont’s agriculture, materials science and specialty products businesses in one or more tax efficient transactions on anticipated terms (the “Intended Business Separations”). Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause DowDuPont’s, Dow’s or DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) successful integration of the respective agriculture, materials science and specialty products businesses of Dow and DuPont, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, productivity actions, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the combined operations; (ii) impact of the divestitures required as a condition to consummation of the Merger Transaction as well as other conditional commitments; (iii) achievement of the anticipated synergies by DowDuPont’s agriculture, materials science and specialty products businesses; (iv) risks associated with the Intended Business Separations, including those that may result from the comprehensive portfolio review undertaken by the DowDuPont board, changes and timing, including a number of conditions which could delay, prevent or otherwise adversely affect the proposed transactions, including possible issues or delays in obtaining required regulatory approvals or clearances related to the Intended Business Separations, disruptions in the financial markets or other potential barriers; (v) the risk that disruptions from the Intended Business Separations will harm DowDuPont’s business (either directly or as conducted by and through Dow or DuPont), including current plans and operations; (vi) the ability to retain and hire key personnel; (vii) potential adverse reactions or changes to business relationships resulting from the completion of the merger or the Intended Business Separations; (viii) uncertainty as to the long-term value of DowDuPont common stock; (ix) continued availability of capital and financing and rating agency actions; (x) legislative, regulatory and economic developments; (xi) potential business uncertainty, including changes to existing business relationships, during the pendency of the Intended Business Separations that could affect the company’s financial performance and (xii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the merger and the Intended Business Separations, are more fully discussed in (1) the Registration Statement and (2) the current, quarterly and annual reports filed with the SEC by DowDuPont and to the extent incorporated by reference into the Registration Statement, by Dow and DuPont. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DowDuPont’s, Dow’s or DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. None of DowDuPont, Dow or DuPont assumes any obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

#   #   #

10/30/17

The DuPont Oval logo, DuPont™ and all products, unless otherwise noted, denoted with ™, ?or ® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates.

Contact:

Wendy Rosen           

+1-650-284-6429

wendy.rosen@dupont.com

@DuPontBioBased